{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076560","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.019187+00:00","generated_at":"2026-05-15T23:52:31.188146+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicara raises $161.8M in public offering; reports preliminary cash of $414.8M","bullets":["Net proceeds of ~$161.8M from offering of 7.175M shares at $16.00/sh and 2.2M pre-funded warrants.","Preliminary unaudited cash, cash equivalents and investments as of Dec 31, 2025: ~$414.8M.","Proceeds to support commercial infrastructure for ficerafusp alfa, accelerated development, and manufacturing.","Underwriters exercised option for additional 1,406,250 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076560","json":"https://secwatch.observer/filing/0001193125-26-076560.json","markdown":"https://secwatch.observer/filing/0001193125-26-076560.md","text":"https://secwatch.observer/filing/0001193125-26-076560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/0001193125-26-076560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/d938194d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:52:31.188146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5967876b1f00ae1cadd96488c82741c951686e47","claim":"Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).","evidence_excerpt":"On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/0001193125-26-076560-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives"},{"label":"Effective","value":"2026-02-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}